R&G PharmaStudies Co., Ltd. (SHE:301333)
China · Delayed Price · Currency is CNY 62.13
+2.05 (3.41%)
Mar 27, 2026, 4:00 PM EDT
R&G PharmaStudies Revenue
In the year 2025, R&G PharmaStudies had annual revenue of 851.01M CNY with 14.38% growth. R&G PharmaStudies had revenue of 243.64M in the quarter ending December 31, 2025, with 33.81% growth.
Revenue
851.01M
Revenue Growth
+14.38%
P/S Ratio
6.95
Revenue / Employee
385.42K
Employees
2,208
Market Cap
5.91B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 851.01M | 107.00M | 14.38% |
| Dec 31, 2024 | 744.00M | 22.63M | 3.14% |
| Dec 31, 2023 | 721.37M | 83.85M | 13.15% |
| Jan 1, 2023 | 637.52M | 29.09M | 4.78% |
| Jan 1, 2022 | 608.43M | 123.98M | 25.59% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2013 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Novogene | 2.17B |
| Kexing Biopharm | 1.54B |
| Xiangxue Pharmaceutical | 1.47B |
| Shenzhen Weiguang Biological Products | 1.14B |
| Wuhan Keqian Biology Co.,Ltd | 950.29M |
| Beijing Konruns Pharmaceutical | 871.31M |
| GemPharmatech | 793.25M |
| Jiangsu Aidea Pharmaceutical Group | 720.67M |